scholarly journals Toxic epidermal necrolysis associated with combination therapy of spironolactone and torsemide

2020 ◽  
Vol 1 (1) ◽  
pp. 19-21 ◽  
Author(s):  
Melcy Mary Philip ◽  
Kala Kesavan P ◽  
Jai Prakash

Introduction: Dytor plus tablet is a fixed-dose combination of torsemide and spironolactone used for generalized edema. TEN is a serious, potentially life-threatening dermatological disorder. Methods: Here we present a case report of a 47-year-old female who was on Dytor Plus (5/50 mg)therapy once daily for generalized edema; presented to dermatology outpatient department with chief complaints of multiple erosions over oral cavity, swelling of lips with scaling, redness and burning sensation in both eyes, multiple well defined mostly erythematous rashes over the entire body since 2 days. Results: On examination, her vital signs were stable and lab results indicate she had elevated SGOT(140 IU/L), SGPT (228 IU/L), ALP (162IU/L), and blood urea(47 mg/ml) values. The patient was diagnosed to have developed Dytor plus induced toxic epidermal necrolysis. Discontinued the medicine and prescribed with Dexamethasone injection, IgG Injection, Cefotaxime injection, Cloxacilline capsule, Cetirizine tablet, Hydroxypropyl methylcellulose eye drop, and candid mouth paint. The patient had a hospital stay of 25 days. Conclusions: The patient improved symptomatically. Causality was assessed as per the WHO-UMC causality scale and this case was put in the probable category. This case was uploaded via vigiflow under the pharmacovigilance programme of India having report Id 2019-30695.

Author(s):  
Mark J. Naccarato ◽  
Deborah M. Yoong ◽  
Ignatius W. Fong ◽  
Kevin A. Gough ◽  
Marian A. Ostrowski ◽  
...  

Background: Patients with drug-resistant HIV often require complex antiretroviral regimens. However, combining fixed-dose combination tablets such as tenofovir–disoproxil–fumarate, emtricitabine, and cobicistat-boosted elvitegravir (TDF/FTC/EVG/cobi) with darunavir (DRV) can provide a simple, once-daily (QD), 2-tablet regimen for patients with drug-resistant HIV. Primary objective was to determine the percentage of patients with HIV-1 RNA <40 copies/mL at 48 weeks. Methods: We performed a retrospective chart review of patients initiated on TDF/FTC/EVG/cobi plus DRV. Results: Among the 21 included patients, prior resistance showed a median of 2 nucleoside reverse transcriptase inhibitor mutations, 1 nonnucleoside reverse transcriptase mutation, and 1 protease inhibitor mutation. At week 48, 14 (67%) patients achieved HIV-1 RNA <40 copies/mL, 1 patient experienced viral rebound, and 6 (29%) had missing data or discontinued therapy. No patient discontinued for adverse events. Conclusion: According to this observational study, QD TDF/FTC/EVG/cobi plus DRV is considered safe, well tolerated, and generally effective in suppressing HIV drug-resistant virus.


Haemophilia ◽  
2015 ◽  
Vol 22 (2) ◽  
pp. 214-217 ◽  
Author(s):  
C. A. M. Stedman ◽  
R. H. Hyland ◽  
X. Ding ◽  
P. S. Pang ◽  
J. G. McHutchison ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document